Anti-angiogenic drug aflibercept (VEGF-Trap) failed to improve overall survival in a Phase III trial in non-small-cell lung cancer, news that came as no surprise to analysts who have criticized Regeneron Pharmaceuticals Inc.'s and partner Paris-based Sanofi-Aventis SA's aggressive move into late-stage trials.